Form 4: Kyverna Therapeutics CFO Marc Grasso Granted 450,000 Stock Options

Kyverna Therapeutics, Inc. Chief Financial Officer Marc Grasso was granted 450,000 stock options with an exercise price of $3.07, aligning his interests with shareholder value.

Summary

• Marc Grasso, Chief Financial Officer of Kyverna Therapeutics, Inc. (KYTX), was granted 450,000 stock options.
• The options have an exercise price of $3.07 per share.
• The earliest transaction date for this grant is June 30, 2025.
• The options begin vesting on June 30, 2026, with 1/4th of the shares vesting on that date.
• Following the initial vesting, 1/48th of the shares will vest each month thereafter.
• Vesting is contingent upon Mr. Grasso's continuous service to Kyverna Therapeutics, Inc.
• The stock options are set to expire on June 30, 2035.
• Following this reported transaction, Mr. Grasso beneficially owns 450,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is generally viewed as a positive step towards aligning management's interests with those of shareholders, reflecting a commitment to long-term performance. This is a routine compensation event.

Positives

• The grant of stock options to the Chief Financial Officer aligns management's long-term interests with those of shareholders, incentivizing performance and value creation.
• This is a standard practice in executive compensation, reflecting a commitment to retaining key talent.

Risks

• No specific risks are detailed in this transactional filing, which primarily reports changes in beneficial ownership of securities.

Future Outlook

The vesting schedule for the stock options, extending through monthly increments after the initial vesting in June 2026, indicates a long-term commitment from the Chief Financial Officer to the company's future performance and growth, contingent on continuous service.

Industry Context

The granting of stock options to key executives like the Chief Financial Officer is a common and established practice within the biotechnology and pharmaceutical industries, serving as a primary component of long-term incentive compensation to attract, retain, and motivate senior leadership.

Comparison to Industry Standards

• The grant of stock options to a Chief Financial Officer is a standard component of executive compensation packages across the biotechnology and broader corporate landscape, designed to align executive incentives with shareholder value creation.
• While specific comparable companies or projects are not detailed in this filing, the structure of the option grant, including a multi-year vesting schedule, is consistent with typical industry practices for long-term executive incentives.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of stock options to the CFO aims to align his financial interests with those of shareholders, potentially leading to increased focus on long-term stock performance and value creation.
• Employees: The CFO's continued commitment, as evidenced by the vesting schedule, can signal stability and confidence in the company's future direction to other employees.

Next Steps

• The vesting of the stock options will occur in scheduled increments, beginning on June 30, 2026, and continuing monthly thereafter, subject to the Chief Financial Officer's continuous service.

Key Dates

Keywords

Kyverna Therapeutics, KYTX, Marc Grasso, Chief Financial Officer, CFO, stock options, insider transaction, executive compensation, Form 4, beneficial ownership